Twist Bioscience SVP Dennis Cho sells $57,590 in company stock
On September 21, 2026, Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience Corp, Dennis Cho, sold 348 shares of the company's common stock. Each share was sold at $165.491, totalling $57,590. This sale was made to satisfy tax withholding obligations linked to the vesting of Restricted Stock Units, as mandated by Twist Bioscience's equity incentive plans.
Cho's direct ownership of the company's stock increased to 73,303 shares following this transaction, which was not a discretionary trade. Twist Bioscience has also formed a partnership with Lilly TuneLab to provide antibody characterization data services, and has filed a prospectus supplement for the resale of shares issued to Invenra Inc. Analyst opinions on Twist Bioscience are mixed, with BWS Financial rating the company as a sell due to competitive pressures, while Guggenheim maintains a Buy rating, recognizing the potential in AI-enabled drug discovery.
Short seller Scorpion Capital has expressed doubt about Twist Bioscience's AI partnership claims, particularly its association with Anthropic.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
